Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

NCT02686658 is registered in ClinicalTrials.gov with IVERIC bio, Inc. as lead sponsor.

NCT NCT02686658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02686658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Lead sponsor
IVERIC bio, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
December 15, 2015
Completion date
April 23, 2020
Enrollment
286 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration, geographic atrophy